Envoy Medical, Inc. (COCH) - Dilution Analysis

10-Q filing | 76.9M shares outstanding

10-K filing | 76.9M shares outstanding

8-K filing: Envoy Medical, Inc. amended the terms of outstanding Stock Purchase Warrants held by Meteora Special Opportunity Fund I, LP, Meteora Capital Partners, LP, Meteora Select Trading Opportunities Master, LP and Meteora Strategic Capital, LLC to extend the expiration date from December 31, 2025, to December 31, 2026, while maintaining a minimum exercise price of $1.50 per share.

S-1 filing: Envoy Medical, Inc. is offering common stock and pre-funded warrants in a direct offering, with the Placement Agent using reasonable best efforts to solicit offers.

S-1/A filing: The selling stockholders of Envoy Medical, Inc. may offer and resell under this prospectus up to 15,116,472 shares of our Class A Common Stock.

S-1 filing: The selling stockholders of Envoy Medical, Inc. may offer and resell up to 15,116,472 shares of Class A Common Stock.

8-K filing: Envoy Medical, Inc. entered into a Securities Purchase Agreement to issue 3,007,524 shares of Class A common stock at $1.33 per share in a registered direct offering and issue warrants to purchase up to 9,022,572 shares of common stock in a concurrent private placement. ($4.0M proceeds)

8-K filing: Envoy Medical, Inc. entered into a Securities Purchase Agreement to issue and sell 1,908,402 shares of Class A common stock at $1.31 per share in a registered direct offering, and agreed to issue warrants to purchase up to 5,725,206 shares of common stock in a concurrent private placement. ($2.5M proceeds)

8-K filing: Envoy Medical, Inc. entered into a Voting and Warrant Extension Agreement with Glen A. Taylor, GAT Funding, LLC, and Taylor Sports Group, Inc., extending the expiration date of warrants held by GAT to purchase 3,500,000 shares of the Company's Class A Common Stock to December 31, 2028.

10-Q filing | 21.4M shares outstanding

POS AM filing: This POS AM filing relates to an offering of up to 17,718,328 shares of Class A Common Stock by Selling Securityholders.

8-K filing: Envoy Medical, Inc. amended the exercise price of the 3,209,511 outstanding Shortfall Warrants held by the Meteora Parties, with the exercise price determined based on a VWAP formula subject to a minimum price of $1.50 per share.

8-K filing: Envoy Medical, Inc. issued GAT Funding, LLC a warrant to purchase 750,000 shares of its Class A Common Stock at an exercise price of $1.48 as a commitment fee for an additional draw under a promissory note.

10-Q filing | 21.3M shares outstanding

10-K filing | 21.3M shares outstanding

8-K filing: Envoy Medical, Inc. issued warrants to GAT Funding, LLC to purchase 750,000 shares of Class A Common Stock at an exercise price of $1.35 per share as a commitment fee for a $5,000,000 tranche of a promissory note.

8-K filing: Envoy Medical, Inc. and Meteora FPA Parties entered into Amendment No. 2 to the Common Stock Purchase Warrant, extending the expiration date of the Shortfall Warrants by 12 months, from December 31, 2024 to December 31, 2025.

8-K filing: Envoy Medical, Inc. entered into a Conversion and Waiver Agreement with Anzu SPAC GP I LLC, involving the waiver of accrued dividends, removal of restrictions on Common Stock, a temporary reduction in the conversion price of Preferred Stock, and the conversion of Preferred Stock into Common Stock.

8-K filing: Envoy Medical, Inc. issued GAT Funding, LLC a warrant to purchase 500,000 shares of its Class A Common Stock as a commitment fee for a $5,000,000 draw under a promissory note.

10-Q filing | 19.6M shares outstanding

S-3 filing: Envoy Medical, Inc. files an S-3 registration statement for the potential offering of Class A Common Stock, Preferred Stock, Warrants, Debt Securities, and Units, with a maximum aggregate offering price of $75,000,000.

8-K filing: Envoy Medical, Inc. entered into a promissory note agreement with GAT Funding, LLC for up to $10,000,000, with an initial draw of $5,000,000 and issued warrants to purchase 500,000 shares of Class A Common Stock at an exercise price of $2.97 per share.

10-Q filing | 19.6M shares outstanding

8-K filing: Envoy Medical, Inc. amended its Forward Purchase Agreement with Meteora FPA Parties on July 29, 2024, to change the exercise price of certain Shortfall Warrants, setting the Exercise Price Floor at $2.00 for 1,000,000 warrants and $3.00 for another 1,000,000 warrants, while the remaining warrants retain the $4.00 Exercise Price Floor.

8-K filing: Envoy Medical, Inc. issued a warrant to GAT Funding, LLC to purchase 250,000 shares of its Class A Common Stock at an exercise price of $2.25 per share as a commitment fee for a $2,500,000 draw under a promissory note.

8-K filing: Envoy Medical, Inc. and the Meteora FPA Parties amended the Common Stock Purchase Warrant, extending the expiration date of the Shortfall Warrants by six months to December 31, 2024.

8-K filing: Envoy Medical, Inc. drew $2,500,000 under a promissory note from GAT Funding, LLC, and issued GAT a warrant to purchase 250,000 shares of its Class A Common Stock with an exercise price of $3.04.

10-Q filing | 19.6M shares outstanding

S-1/A filing: This S-1/A filing relates to the issuance by the company of up to 21,954,103 shares of Class A common stock issuable upon exercise of warrants and conversion of preferred stock, as well as the offer and sale from time to time by selling securityholders of up to 3,874,394 Shortfall Warrants and up to 21,206,360 shares of Class A Common Stock.

S-1/A filing: This S-1/A filing relates to the issuance by the company of up to 21,954,103 shares of Class A common stock, issuable upon the exercise of warrants and conversion of preferred stock, and the offer and sale by selling securityholders of up to 21,206,360 shares of Class A common stock and 3,874,394 warrants.

10-K filing | 19.6M shares outstanding

8-K filing: Envoy Medical, Inc. issued a promissory note for up to $10,000,000 to GAT Funding, LLC, and as a commitment fee, the Company issued warrants to purchase 500,000 shares of its Class A Common Stock at an exercise price of $1.24 per share.

S-1/A filing: This S-1/A filing includes the issuance of Class A common stock upon exercise of warrants and conversion of preferred stock by the company, and the offer and sale of Class A common stock and warrants by selling securityholders.

S-1 filing: This S-1 filing registers the issuance of Class A common stock upon exercise of warrants and conversion of preferred stock, as well as the resale of Class A common stock and warrants by selling securityholders.

10-Q filing | 19.5M shares outstanding

8-K filing: Issuance of unregistered securities including common and preferred stock, adoption of amended corporate documents, and agreements related to director indemnification and registration rights. ($20.0M proceeds)

8-K filing: Anzu Class A Common Stock holders redeemed 2,386,294 shares at approximately $10.46 per share for $25.0 million in aggregate, and the company transferred 8,512 shares of Class A Common Stock to Seller on September 29, 2023, as part of a Forward Purchase Agreement. ($25.0M proceeds)

10-Q filing | 10.6M shares outstanding

10-Q filing | 10.6M shares outstanding

8-K filing: Anzu Special Acquisition Corp I entered into a business combination agreement with Envoy Medical Corporation, involving the merger of Merger Sub with Envoy, resulting in Envoy becoming a wholly-owned subsidiary of Anzu. Anzu will issue shares of Series A Preferred Stock to the Sponsor and the Company Bridge Note Holder in private placements. ($10.0M proceeds)

10-K filing | 10.6M shares outstanding

8-K filing: Anzu Special Acquisition Corp I stockholders holding 38,187,226 Public Shares exercised their right to redeem their shares for a pro rata portion of the funds in a trust account, resulting in approximately $387.5 million being removed from the Trust Account and leaving 4,312,774 Public Shares outstanding. ($387.5M proceeds)

8-K filing: Anzu Special Acquisition Corp I entered into extension support agreements with several unaffiliated third parties, where the Sponsor agreed to transfer 20,000 shares of the Company's Class B common stock to each Holder for every 100,000 Public Shares held by such Holder immediately following the Special Meeting, up to a maximum of 80,000 Founder Shares to each Holder, in exchange for the Holder agreeing to vote in favor of the Extension Amendment Proposal.

10-Q filing | 10.6M shares outstanding

10-Q filing | 10.6M shares outstanding

10-Q filing | 10.6M shares outstanding

10-K filing | 10.6M shares outstanding

8-K filing: Anzu Special Acquisition Corp I entered into Forward Purchase Agreements to sell up to $80,000,000 of unsecured convertible notes and up to 4,000,000 forward purchase securities for $10.00 per security, totaling up to $40,000,000, immediately prior to the Business Combination Closing. ($40.0M proceeds)

10-Q filing | 10.6M shares outstanding

10-Q filing | 4.3M shares outstanding

10-Q filing | 42.0M shares outstanding

8-K filing: Anzu Special Acquisition Corp I consummated its initial public offering of 42,000,000 units at $10.00 per unit, generating gross proceeds of $420,000,000, and completed the private sale of 12,400,000 warrants at $1.00 per warrant, generating gross proceeds of $12,400,000. ($437.5M proceeds)

8-K filing: Anzu Special Acquisition Corp I consummated its initial public offering of 42,000,000 units at $10.00 per unit, generating gross proceeds of $420,000,000, and completed a private placement of 12,400,000 warrants at $1.00 per warrant to its sponsor, generating gross proceeds of approximately $12,400,000. ($432.4M proceeds)

8-K filing: Anzu Special Acquisition Corp I consummated its IPO of 42,000,000 units at $10.00 per unit, generating gross proceeds of $420,000,000, and effected a stock dividend of 2,012,500 shares of Class B Common Stock. Simultaneously, the Company completed the private sale of 12,400,000 warrants to the Sponsor at $1.00 per warrant, generating gross proceeds of $12,400,000. ($432.4M proceeds)

S-1/A filing: An initial public offering of units, each consisting of one share of Class A common stock and one-third of one redeemable warrant, and private placement warrants.

S-1 filing: An initial public offering of 25,000,000 units at $10.00 per unit, each unit consisting of one share of Class A common stock and one-half of one redeemable warrant, and private placement warrants at $1.00 per warrant.